1005738-45-3

Usage

Uses

Used in Pharmaceutical Industry:
Piperidine-1,4,4-tricarboxylic acid 1-tert-butyl ester 4-Methyl ester serves as an intermediate or building block in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic targets, potentially leading to advancements in medicinal chemistry.
Used in Chemical Industry:
In the chemical industry, Piperidine-1,4,4-tricarboxylic acid 1-tert-butyl ester 4-Methyl ester may be utilized as a reagent or catalyst in various chemical processes. Its functional groups can participate in a range of reactions, contributing to the synthesis of other complex organic molecules.
Used in Organic Synthesis:
As a key component in organic synthesis, Piperidine-1,4,4-tricarboxylic acid 1-tert-butyl ester 4-Methyl ester is employed for constructing complex organic molecules. Its versatility in forming different types of chemical bonds makes it a valuable precursor in the creation of novel organic compounds for research and commercial applications.
The specific applications and properties of Piperidine-1,4,4-tricarboxylic acid 1-tert-butyl ester 4-Methyl ester are likely to be the focus of ongoing research and development, with the potential to expand its use across multiple industries.

Upstream product

• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2971-79-1 isonipecotic acid methyl ester 
• 495415-40-2 1-tert-butyl 4,4-dimethyl piperidine-1,4,4-tricarboxylate 

Downstream Products

• 1005738-46-4 1-tert-butyl 4-methyl 4-(2-chlorobenzylcarbamoyl)piperidine-1,4-dicarboxylate 
• 1006044-27-4 1-tert-butyl 4-methyl 4-(hydroxymethyl)piperidine-1,4-dicarboxylate 

Relevant academic research and scientific papers

Quinoline multi-target kinase inhibitor with antitumor activity and preparation method thereof

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

Certain Chemical Entities, Compositions and Methods

Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.